Clinical Trials Logo

Clinical Trial Details — Status: Not yet recruiting

Administrative data

NCT number NCT05147818
Other study ID # SSA
Secondary ID
Status Not yet recruiting
Phase
First received
Last updated
Start date December 1, 2021
Est. completion date December 30, 2023

Study information

Verified date November 2021
Source Assiut University
Contact n/a
Is FDA regulated No
Health authority
Study type Observational

Clinical Trial Summary

incidence of AKI in diabetic patients seems to be influenced by multiple risk Factors like severe infections, elderly, poor diabetic control, previous AKI, chronic kidney disease and drugs like SGLT2-I increase risk of AKI in diabetic patients.


Description:

The incidence and prevalence of diabetes mellitus (DM) have increased over the last 20 years. The defining feature of diabetes mellitus (DM) is the presence of hyperglycaemia . mostly due to the progressively increasing prevalence of obesity and the metabolic syndrome, Current prevalence of DM worldwide is estimated to be about 390 million people . The Cardiovascular complications increase morbidity and mortality in diabetic patients. About 40% of end-stage renal disease on regular dialysis are diabetic . Acute kidney injury (AKI) Is a fundamental problem in hospitalized patients; its incidence has been reaching 20% in middle-Europe . About 50% of patients presented with AKI are found to be diabetic ; which may indicate a direct relationship between the two conditions. In 2012, a clinical practice guideline published by Kidney Disease: Improving Global Outcomes (KDIGO) provided a unifying definition and staging system for AKI . On the other hand, incidence of AKI in diabetic patients seems to be influenced by multiple risk Factors like severe infections, elderly, poor diabetic control, previous AKI, chronic kidney disease and drugs like SGLT2-I increase risk of AKI in diabetic patients. We aim in this study to identify the most common risk factors for AKI in diabetic patients and how those risk factors affect morbidity and mortality in patients with DM who developed AKI.


Recruitment information / eligibility

Status Not yet recruiting
Enrollment 400
Est. completion date December 30, 2023
Est. primary completion date December 30, 2023
Accepts healthy volunteers
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: - Inclusion criteria for the cases : 200 Diabetic patients of 18 year and older (either type 1or 2) presented by AKI based on KIDIGO Definition & Staging. KDIGO definition of AKI: Increase in serum creatinine by =0.3 mg/dL (=26.5 µmol/L) within 48 h, or Increase in serum creatinine to =1.5 times baseline that is known or presumed to have occurred within the prior 7 days, or Urine volume <0.5 mL/kg/h for 6 h. KDIGO staging of AKI: (1) stage 1: Serum creatinine 1.5-1.9 × baseline or =0.3 mg/dL (=26.5 µmol/L) increase / Urine output <0.5 mL/kg/h for 6-12 h (2) stage 2; Serum creatinine 2.0-2.9 × baseline / Urine output <0.5 mL/kg/h for =12 h (3) stage 3: Serum creatinine 3.0 × baseline, increase in serum creatinine to =4.0 mg/dL (=353.6 µmol/L), initiation of renal replacement therapy, or, in patients <18 years, decrease in eGFR to <35 mL/min per 1.73 m2 / Urine output <0.3 mL/kg/h for =24 h or anuria for =12 h . Inclusion criteria for matched controls 200 Diabetic patients of 18 year and older with no AKI (either type 1or 2) Exclusion Criteria: Exclusion criteria for cases and controls: 1. Non-Diabetic patients with AKI 2. Diabetic patients with: - HBS Ag, HCV, HIV - Active Lupus - Active Malignancy - Acute or Chronic Liver Disease - Acute poisoning

Study Design


Related Conditions & MeSH terms


Intervention

Other:
CBC ,renal function tests , fundus Examination
Laboratory investigations

Locations

Country Name City State
n/a

Sponsors (1)

Lead Sponsor Collaborator
Assiut University

References & Publications (5)

American Diabetes Association. (2) Classification and diagnosis of diabetes. Diabetes Care. 2015 Jan;38 Suppl:S8-S16. doi: 10.2337/dc15-S005. Review. — View Citation

Aziz Z, Absetz P, Oldroyd J, Pronk NP, Oldenburg B. A systematic review of real-world diabetes prevention programs: learnings from the last 15 years. Implement Sci. 2015 Dec 15;10:172. doi: 10.1186/s13012-015-0354-6. Review. — View Citation

Bienholz A, Wilde B, Kribben A. From the nephrologist's point of view: diversity of causes and clinical features of acute kidney injury. Clin Kidney J. 2015 Aug;8(4):405-14. doi: 10.1093/ckj/sfv043. Epub 2015 Jul 9. — View Citation

DeFronzo RA, Reeves WB, Awad AS. Pathophysiology of diabetic kidney disease: impact of SGLT2 inhibitors. Nat Rev Nephrol. 2021 May;17(5):319-334. doi: 10.1038/s41581-021-00393-8. Epub 2021 Feb 5. Review. — View Citation

Mima A. Diabetic nephropathy: protective factors and a new therapeutic paradigm. J Diabetes Complications. 2013 Sep-Oct;27(5):526-30. doi: 10.1016/j.jdiacomp.2013.03.003. Epub 2013 Apr 22. Review. — View Citation

Outcome

Type Measure Description Time frame Safety issue
Primary Identify risk factors for Acute kidney injury in diabetic patients Identify risk factors for Acute kidney injury in d iabetic patients 2 years
See also
  Status Clinical Trial Phase
Recruiting NCT05563090 - Investigating the Syndrome Differentiation of Diabetic and Pre-diabetic Using Digitalized TCM Diagnostic Tools
Recruiting NCT05333159 - The Efficacy of SGLT-2 Inhibitor in Patients With CAD and DM Undergoing PCI.
Active, not recruiting NCT03119584 - Efficacy of Linaclotide in Type II Diabetics With Chronic Constipation Phase 4
Completed NCT04409171 - Glucose Metabolism After Partial Pancreatectomy
Recruiting NCT06060392 - Effect of Oral Semaglutide on Liver Fat and Body Composition in Liver Transplant Recipients With Diabetes Mellitus N/A
Completed NCT05144971 - StatStrip A Glucose/Creatinine Meter System Lay User Study Evaluation
Completed NCT03914183 - Can mCPN Intervention Improve Injection Site Rotation N/A
Completed NCT03781232 - Non-invasive Glucose Measurement With Raman Technology in Patients With Type 1 and Type 2 Diabetes N/A
Not yet recruiting NCT06150508 - Randomized Controlled Trial of the Smart O2O Model Development for Chronic Diseases Management Through Digital Health N/A
Completed NCT01252810 - Safety Study of GE-145 320 mg I/mL Injection vs. Iopamidol 370 mg I/mL in Elderly Subjects Undergoing Coronary Procedure Phase 2
Active, not recruiting NCT04171557 - Bicycling and Mortality Among Individuals With diabetesNutrition (EPIC)
Active, not recruiting NCT03155594 - CGM to Aid Transition From Inpatient to Outpatient N/A
Completed NCT04864327 - Smoking Intervention Among Patients With Diabetes N/A
Completed NCT04407182 - Safety and Efficacy of Viusid and Asbrip in Hospitalized Patients Infected by SARS-Cov-2 With COVID-19 Phase 2
Completed NCT05752591 - Hypothalamic-pituitary Dysfunction in Diabetes
Completed NCT03159546 - FreeStyle Libre Flash Glucose Monitoring System Accuracy N/A
Completed NCT03953092 - A Randomized, Double-blind, Placebo-controlled, Sequential Single and Multiple Ascending Doses of YG1699 Phase 1
Not yet recruiting NCT06262854 - Efficacy and Safety of Stimulan® for the Treatment of Diabetic Foot Osteomyelitis. The BIG D-FOOT Study N/A
Completed NCT03934281 - Study of the Value of Using a Honey Dressing Compared to the Use of a Standard Dressing on the Toe Amputation Wound in the Diabetic Patient N/A
Not yet recruiting NCT03341026 - Metronom Continuous Glucose Monitoring System N/A